E400P in advanced seminoma of good prognosis according to the International Germ Cell Collaborative Group (IGCCCG) classification: The Spanish Germ Cell Cancer Group experience

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 487-491

  Arranz Arija, J A ^a   Garcia Del Muro X ^b   Guma J ^c   Aparicio, J ^d   Salazar, R ^e   Saenz, A ⁱ   Carles, J ^f   Sanchez M ^g   Germa Lluch J R ^b,h  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL SANT PAU   (Spain)

^f Department of Dermatology   (Spain)

^g Hospital Nuestra Senora de Aranzazu   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ NONE

Author keywords

Advanced seminoma; Cisplatin etoposide; Germ cell tumour; Testicular cancer

Indexed keywords

CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; EXPERIENCE; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SEMINOMA; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0035018020     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011127715764     Document Type: Article

References (21)

1. Gospodarowicz MK, Sturgeon JFG and Jewett MAS. Ealrly stage and advanced seminoma: Role of radiation therapy, surgery and chemotherapy. Semin Oncol 1998; 25: 160-73.
2. International Germ Cell Cancer Collaborative Group. International germ-cell consensus classification: A prognostic factor-based staging system for metastatic germ-cell cancers. J Clin Oncol 19997; 15: 594-603.
3. Fossá SD, Oliver RTD, Stenning SP et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 1997; 33: 1380-7.
4. Zagars G, Babaian J. The role of radiation in stage II testicular seminoma. Int J Radiat Oncol Biol Phys 1987; 13: 163-70.
5. Warde P, Gospodarowicz M, Panzarella T et al. Management of stage II seminoma. J Clin Oncol 1998; 16: 290-4.
6. Bokemeyer C, Schmoll HJ. Treatment of testicular cancer and the developemenl of secondary malignancies. J Clin Oncol 1995; 13: 283-92.
7. Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ-cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7: 387-91.
8. Loehrer PJ, Johnson DH, Elson Pet al. Importance of bleomycin in favorable-prognosis disseminated germ-cell tumors: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995; 13: 470-6.
9. Mencel PJ, Motzer RJ, mazumdar M et al. Avanced seminoma: Treatment results, survival and prognostic factors in 142 patients. J Clin Oncol 1994; 12: 120-6.
10. Culline S, Kerbrat P, Bouzy C et al. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent regimens for patients with good-risk metastatic non seminomatous germ-cell tumors? Prelimary results of randomized trial. Proc Am Soc Clin Oncol 1999; 18: 309a.
11. Kollmannsberger C, Beyer J, Droz JP et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ-cell tumors. J Clin Oncol 1998; 16: 3386-91.
12. de Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: A randomized study of the EORTC and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15(5): 1837-43.
13. de Wit R, Roberts JT, Wilkinson P et al. Final analysis demonstrating the equivalence of 3 bep vs. 4 cycles and the 5 day schedule vs. 3 days per cycle in good prognosis germ cell cancer. An EORTC/MRC phase III study. Proc Am Soc Clin Oncol 2000; 19: 326a.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
15. Moller H, Mellengaard A, Jacobsen GK et al. Incidence of second primary cancer following testicular cancer. Eur J Cancer 1993; 5: 672-6.
16. van Leeuwen F, Stiggelbout AM, van den Belt-Dusebout AW et al. Second cancer risk following testicular cancer. A follow-up study of 1909 patients. J Clin Oncol 1993; 11: 415-24.
17. Travis L, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429-39.
18. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ-cell tumors: A multiinstitutional study. J Clin Oncol 1993; 11: 598-606.
19. Norwich A, Sleiifer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic non-seminomatous germ-cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 1997; 15: 1844-52.
20. Horwich A, Oliver RTD, Fossa SD et al. A randomised MRC trial comparing single-agent carboplatin with the combination of etoposide and cisplatin in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 1996; 15 (Abstr 668).
21. Saxman SB, Finch D, Gonin R et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 1998; 16: 702-6.